Literature DB >> 9097909

Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease.

R Giacomelli1, P Cipriani, R Lattanzio, M Di Franco, M Locanto, I Parzanese, A Passacantando, A Ciocci, G Tonietti.   

Abstract

Activated Th2 lymphocytes express the surface molecule CD30 and release a soluble form of the same molecule which can be detected both in vivo and in vitro. In the present study, high levels of soluble CD30 were found in the peripheral blood of patients with SSc, and a significant correlation with skin score and erythrocyte sedimentation rate (ESR) was detected. Furthermore, we observed a higher spontaneous release of soluble CD30 in the supernatants of unstimulated cultures of peripheral blood mononuclear cells from our patients compared with healthy controls. Taken together, these data suggest a possible involvement of Th2 cells in the immunopathogenesis of SSc, and the dosage of CD30 soluble in the peripheral blood may be helpful in following the outcome of the disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9097909      PMCID: PMC1904632          DOI: 10.1046/j.1365-2249.1997.d01-991.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  12 in total

Review 1.  The Th1/Th2 paradigm in the pathogenesis of scleroderma, and its modulation by thalidomide.

Authors:  S J Oliver
Journal:  Curr Rheumatol Rep       Date:  2000-12       Impact factor: 4.592

2.  Circulating gamma/delta T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization.

Authors:  R Giacomelli; P Cipriani; A Fulminis; G Barattelli; M Matucci-Cerinic; S D'Alò; G Cifone; G Tonietti
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

3.  Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation.

Authors:  G Valentini; A Baroni; K Esposito; C Naclerio; E Buommino; A Farzati; G Cuomo; B Farzati
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

4.  Serum levels of soluble CD30 are increased in ulcerative colitis (UC) but not in Crohn's disease (CD).

Authors:  R Giacomelli; A Passacantando; I Parzanese; P Vernia; N Klidara; F Cucinelli; R Lattanzio; E Santori; P Cipriani; R Caprilli; G Tonietti
Journal:  Clin Exp Immunol       Date:  1998-03       Impact factor: 4.330

5.  Expression of CD30 mRNA, CD30L mRNA and a variant form of CD30 mRNA in restimulated peripheral blood mononuclear cells (PBMC) of patients with helminthic infections resembling a Th2 disease.

Authors:  J Kilwinski; T Berger; J Mpalaskas; S Reuter; W Flick; P Kern
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

6.  Immunological and clinical follow up of hepatitis C virus associated cryoglobulinaemic vasculitis.

Authors:  P Lamprecht; F Moosig; A Gause; K Herlyn; E Csernok; H Hansen; W L Gross
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

Review 7.  Application of biomarkers to clinical trials in systemic sclerosis.

Authors:  Robert Lafyatis
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

8.  Pregnancy in patients with rheumatic disease: anti-inflammatory cytokines increase in pregnancy and decrease post partum.

Authors:  M Østensen; F Förger; J L Nelson; A Schuhmacher; G Hebisch; P M Villiger
Journal:  Ann Rheum Dis       Date:  2004-11-11       Impact factor: 19.103

9.  Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines.

Authors:  Pravitt Gourh; Sandeep K Agarwal; Dipal Divecha; Shervin Assassi; Gene Paz; Rajpreet K Arora-Singh; John D Reveille; Sanjay Shete; Maureen D Mayes; Frank C Arnett; Filemon K Tan
Journal:  Arthritis Rheum       Date:  2009-12

10.  Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations.

Authors:  Pravitt Gourh; Frank C Arnett; Shervin Assassi; Filemon K Tan; Mei Huang; Laura Diekman; Maureen D Mayes; John D Reveille; Sandeep K Agarwal
Journal:  Arthritis Res Ther       Date:  2009-10-02       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.